IL-12/IL-23p40 identified as a downstream target of apremilast in ex vivo models of arthritis

BACKGROUND: Apremilast (Otezla(®)) is a phosphodiesterase 4 (PDE4) inhibitor approved for the treatment of psoriasis and psoriatic arthritis (PsA), but the reason why apremilast shows clinical effect is not fully understood. The objective of this study was to study the downstream effects of apremila...

Descripción completa

Detalles Bibliográficos
Autores principales: Kragstrup, Tue W., Adams, Mary, Lomholt, Søren, Nielsen, Morten A., Heftdal, Line D., Schafer, Peter, Deleuran, Bent
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391542/
https://www.ncbi.nlm.nih.gov/pubmed/30833991
http://dx.doi.org/10.1177/1759720X19828669

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6391542/
https://www.ncbi.nlm.nih.gov/pubmed/30833991
http://dx.doi.org/10.1177/1759720X19828669

Ejemplares similares